Zoetis Inc. (ZTS): A Bull Case Theory

Insider Monkey2024-12-27

We came across a bullish thesis on Zoetis Inc. (NYSE:ZTS) on Substack by Best Anchor Stocks. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc. (NYSE:ZTS)'s share was trading at ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2494860886?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-27 00:35","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2494860886","market":"us","top_or_hot":-1,"title":"Zoetis Inc. (ZTS): A Bull Case Theory","media":"Insider Monkey","content":"<div>\n<p>We came across a bullish thesis on Zoetis Inc. (NYSE:ZTS) on Substack by Best Anchor Stocks. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc. (NYSE:ZTS)'s share was trading at ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zoetis-inc-zts-bull-case-163521630.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoetis Inc. (ZTS): A Bull Case Theory</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoetis Inc. (ZTS): A Bull Case Theory\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-27 00:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/zoetis-inc-zts-bull-case-163521630.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We came across a bullish thesis on Zoetis Inc. (NYSE:ZTS) on Substack by Best Anchor Stocks. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc. (NYSE:ZTS)'s share was trading at ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zoetis-inc-zts-bull-case-163521630.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0158827948.USD","symbol_name":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/zoetis-inc-zts-bull-case-163521630.html","article_id":"2494860886","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494860886","pubTimestamp":1735230921,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We came across abullish thesison Zoetis Inc.  on Substack by Best Anchor Stocks. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc. 's share was trading at $164.70 as of Dec 24th. ZTS’s trailing and forward P/E were 30.96 and 28.41 respectively according to Yahoo Finance.Zoetis delivered an impressive earnings report a month ago, surpassing revenue and earnings estimates while raising its guidance. Despite the strong performance, its stock dropped post-earnings, though it has since rebounded, maintaining levels similar to before the report. Considering the company's flawless quarter and growth acceleration, this drop was puzzling. Zoetis has posted three consecutive \"beat-beat-raise\" quarters this year, marking its solid momentum. The company’s revenue grew 11% in the quarter, with operational growth of 14%, the highest since the pandemic-driven surge. This accelerating growth contradicts earlier skepticism in 2022, when some analysts labeled Zoetis as a no-growth","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4007":"制药","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","BK4588":"碎股","ZTS":"Zoetis Inc.","LU2308191902.HKD":"BNP PARIBAS ECOSYSTEM RESTORATION \"CLASSIC\" (HKD) ACC","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0385154629.USD":"贝莱德营养科学基金A2","LU0079474960.USD":"联博美国增长基金A","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓"},"translate_title":"硕腾公司(ZTS)：牛市案例理论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZTS":1},"content_text":"We came across a bullish thesis on Zoetis Inc. (NYSE:ZTS) on Substack by Best Anchor Stocks. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc. (NYSE:ZTS)'s share was trading at $164.70 as of Dec 24th. ZTS’s trailing and forward P/E were 30.96 and 28.41 respectively according to Yahoo Finance.\n didesign021/Shutterstock.com \nZoetis delivered an impressive earnings report a month ago, surpassing revenue and earnings estimates while raising its guidance. Despite the strong performance, its stock dropped post-earnings, though it has since rebounded, maintaining levels similar to before the report. Considering the company's flawless quarter and growth acceleration, this drop was puzzling. Zoetis has posted three consecutive \"beat-beat-raise\" quarters this year, marking its solid momentum. The company’s revenue grew 11% in the quarter, with operational growth of 14%, the highest since the pandemic-driven surge. This accelerating growth contradicts earlier skepticism in 2022, when some analysts labeled Zoetis as a no-growth business.\nA major driver behind this growth has been the success of Zoetis' monoclonal antibodies (MABs) for osteoarthritis (OA) pain, namely Librela and Solensia, which have performed exceptionally well in both the U.S. and Europe. These products experienced a 97% operational growth year-over-year, with Librela becoming the fourth-largest product in the U.S. market. In Europe, the MAB franchise continues to expand, with Librela showing strong growth despite its established scale, as the product now treats milder OA cases. This expansion increases the patient population and reduces churn, extending patient retention to 7-8 months, up from 4-5 months just a few years ago.\nZoetis' ability to create new markets is evident in the OA MAB franchise, which was not part of its addressable market (TAM) until recently. Products like Librela and Solensia are now poised to become billion-dollar franchises. Librela, for instance, has already brought nearly 500,000 new patients to the OA pain category in the U.S. While the market expressed concerns about sequential growth for Librela in the U.S., management argued that growth in newly created categories is not always linear, pointing to a similar pattern in Europe the previous year.\nOther Zoetis franchises also performed well, with Simparica and Dermatology showing operational growth of 27% and 16%, respectively. Despite facing competition, Zoetis continues to gain market share in these categories, underscoring its resilient business model. Zoetis contends that competition helps expand the market, and its products maintain strong market positions as long as they are sufficiently differentiated. This has been the case with Simparica Trio, which has grown revenue significantly despite new entrants.\nThe company also managed to balance growth between volume and price increases, with volume contributing 8% growth and price 6%. While veterinary inflation remains a concern, Zoetis' pricing strategy reflects the growing mix of innovative products, which justifies the higher prices.\nZoetis revised its 2024 guidance slightly, increasing revenue growth from 10% to 10.5% but lowering net income growth expectations from 14.5% to 14%. Despite the sale of its feed additive portfolio, which will reduce revenue by about $66 million per quarter, Zoetis remains focused on its core business and the continued rollout of its OA pain MABs. Management expressed confidence in strong growth for 2025 despite competition for products like Apoquel. Overall, Zoetis' strong quarter, broad-based growth, and market leadership in animal health reinforce its position as a growth stock in an expanding industry, driven by the increasing number of pets and their unmet health needs.\nZoetis Inc. (NYSE:ZTS) is not on our list of the 31 Most Popular Stocks Among Hedge Funds. As per our database, 62 hedge fund portfolios held ZTS at the end of the third quarter which was 61 in the previous quarter. While we acknowledge the risk and potential of ZTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ZTS but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.\nREAD NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.\nDisclosure: None. This article was originally published at Insider Monkey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494860886"}